BioCryst Pharmaceuticals | BCRX - Fremdkapital





Fremdkapital Veränderung Datum
Alnylam Pharmaceuticals USD 2.48B 931K 2026-03
BioCryst Pharmaceuticals USD 395.2M 33.48M 2026-03
Chugai Pharma JPY 4.53B 1.95B 2024-12
Daiichi Sankyo JPY 300.15B 199.41B 2025-12
DBV Technologies USD 0 0 2025-03
Enanta Pharmaceuticals USD 0 0 2024-12
Gilead Sciences USD 20.86B 1.27B 2026-03
GlaxoSmithKline GBP 14.01B 696M 2026-03
Glaxosmithkline GBP 19.82B 203.13M 2025-12
Incyte USD 29.41M 785K 2026-03
Ionis Pharmaceuticals USD 1.91B 9M 2026-03
Karyopharm Therapeutics USD 278.22M 278.22M 2025-12
Neurocrine Biosciences USD 169.5M 500K 2023-03
Novavax USD 246.3M 200K 2025-12
PTC Therapeutics USD 286.94M 1.74B 2026-03
Regeneron Pharmaceuticals USD 1.99B 719.7M 2026-03
Roche Holding CHF 27.43B 966M 2025-12
Sarepta Therapeutics USD 838.16M 9.19M 2026-03
Ultragenyx Pharmaceutical USD 1.13B 19M 2026-03
Vertex Pharmaceuticals USD 106.7M 4.7M 2025-12